Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats.
OBJECTIVE
We sought to investigate whether ulinastatin (urinary trypsin inhibitor) inhibited systemic inflammatory responses following lung ischemia-reperfusion (I/R) injury.


METHODS
Establishing a steady left lung warm I/R model in rats, we randomly divided 32 animals into 4 groups: sham (n = 8); I/R (n = 8); low-dose ulinastatin (5000 U/kg pre-ischemia) + I/R (n = 8); and high-dose ulinastatin (10,000 U/kg pre-ischemia) + I/R (n = 8). Measured variables included plasma concentrations of tumor necrosis factor-alpha (TNF-alpha), as well as interleukin (IL)-6 and IL-8.


RESULTS
The serum concentrations of TNF-alpha, IL-6, and IL-8 in the ulinastatin pretreated groups were markedly decreased compared with those of the I/R group (P < .05). The levels of TNF-alpha, IL-6, and IL-8 were lower in the high-dose ulinastatin group compared with the low-dose ulinastatin group (P < .05).


CONCLUSIONS
Ulinastatin produced dose-dependent attenuation of the systemic inflammatory response of rats following lung I/R injury.
Xu
L
L
Department of Thoracic Surgery, Cancer Institute and Hospital of Jiangsu Province, Jiangsu, China.
Ren
B
B
Li
M
M
Jiang
F
F
Zhanng
Z
Z
Hu
J
J
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006023:Glycoproteins / Q000097:blood / Q000627:therapeutic use*; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy*; D013908:Thoracotomy; D014361:Trypsin Inhibitors / Q000097:blood / Q000627:therapeutic use*
D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin